MedTrace Logo

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

NCT05116930 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-03-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.

Conditions

  • Post-Dural Puncture Headache

Interventions

DRUG

Neostigmine

IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses

DRUG

Glycopyrrolate

IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses

Sponsors & Collaborators

Principal Investigators

  • Mark Rollins, MD, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-19
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05116930 on ClinicalTrials.gov